Alzamend Neuro completes Phase IIA MAD trial for AL001; topline data due June 2023

Alzamend Neuro, Inc.

Completed clinical portion of Phase IIA multiple ascending dose trial for AL001 in Alzheimer's dementia.
AL001 is a novel lithium-delivery ionic cocrystal aiming to improve safety over current lithium treatments.
Topline data from the MAD study expected in June 2023.
Trial evaluated safety, tolerability, and maximum tolerated dose in mild-to-moderate Alzheimer's patients and healthy subjects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.